We are live on ! Find out more
MREO

Mereo BioPharma
MREO

53 hedge funds and large institutions have $84.3M invested in Mereo BioPharma in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,668% more call options, than puts

Call options by funds: $775K | Put options by funds: $28K

96% more capital invested

Capital invested by funds: $43M → $84.3M (+$41.3M)

0.59% more ownership

Funds ownership: 9.73% → 10.32% (+0.59%)

9% less funds holding

Funds holding: 58 → 53 (-5)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

57% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 21

Holders
53
Holders Change
-5
Holders Change %
-8.62%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
21
Closed
11
Calls
$775K
Puts
$28K
Net Calls
+$747K
Net Calls Change
+$693K

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$6.42M
2
BBA
Baker Bros. Advisors
New York
+$4.12M
3
6CM
683 Capital Management
New York
+$3.94M
4
Alkeon Capital Management
Alkeon Capital Management
New York
+$1.57M
5
RCMNY
Rubric Capital Management (New York)
New York
+$1.45M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$5.48M
2
Millennium Management
Millennium Management
New York
-$1.8M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.48M
4
Citigroup
Citigroup
New York
-$799K
5
MAM
Monaco Asset Management
Monaco
-$708K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$15.3M +$1.45M +1,250,000 +12%
SCM
2
Suvretta Capital Management
New York
$9.72M – – –
RSCM
3
Rock Springs Capital Management
Maryland
$9.3M +$925K +797,494 +13%
MP
4
Mangrove Partners
Connecticut
$7.3M +$6.42M +5,531,547 New
6CM
5
683 Capital Management
New York
$7.13M +$3.94M +3,400,000 +170%
Alkeon Capital Management
6
Alkeon Capital Management
New York
$4.93M +$1.57M +1,352,500 +57%
BBA
7
Baker Bros. Advisors
New York
$4.69M +$4.12M +3,554,979 New
TC
8
Tejara Capital
United Kingdom
$4.01M +$698K +602,165 +25%
BC
9
Boxer Capital
California
$2.97M – – –
Goldman Sachs
10
Goldman Sachs
New York
$2.62M -$325K -280,379 -12%
CC
11
Clearline Capital
New York
$2.57M -$125K -107,669 -5%
Renaissance Technologies
12
Renaissance Technologies
New York
$2.35M +$1M +862,863 +94%
Citadel Advisors
13
Citadel Advisors
Florida
$2.33M -$1.48M -1,279,517 -42%
TCM
14
Tekla Capital Management
Massachusetts
$2.05M – – –
DCM
15
DAFNA Capital Management
California
$1.33M -$101K -87,500 -8%
Millennium Management
16
Millennium Management
New York
$1.26M -$1.8M -1,550,559 -62%
MAM
17
Monaco Asset Management
Monaco
$932K -$708K -610,516 -46%
JGC
18
J. Goldman & Co
New York
$463K -$298K -256,515 -42%
TI
19
Tidal Investments
Wisconsin
$438K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$401K -$143K -123,102 -29%
IC
21
Ikarian Capital
Texas
$300K +$1.03M +891,676 New
Two Sigma Investments
22
Two Sigma Investments
New York
$261K +$229K +197,759 New
BFM
23
Boothbay Fund Management
New York
$240K -$285K -245,679 -57%
PFMU
24
Privium Fund Management (UK)
United Kingdom
$225K – – –
Primecap Management
25
Primecap Management
California
$208K -$161K -138,830 -47%
1
2 3

MREO Hedge Fund Activity: Q2 2023 in Review

53 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2023, worth a combined $84.3M — up 96% from $43M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of MREO and 6 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 9 added.

The largest buyer was Mangrove Partners, opening a new position worth an estimated $6.42M. The largest seller was OrbiMed, exiting entirely with an estimated $5.48M sold.

  • 53 institutional investors held Mereo BioPharma (MREO) as of Q2 2023, down from 58 in Q1 2023.
  • Funds reported $84.3M of Mereo BioPharma stock for Q2 2023, up 96% quarter-over-quarter.
  • 6 funds opened new Mereo BioPharma positions in Q2 2023 and 11 closed out, a net change of -5 holders.
  • The largest Mereo BioPharma buyer in Q2 2023 was Mangrove Partners, an estimated $6.42M added.
  • The largest Mereo BioPharma seller in Q2 2023 was OrbiMed, an estimated $5.48M sold.

Based on aggregated 13F filings for Q2 2023.